Celanese Expands Capabilities to Support the Sustained-Release Drug Delivery Market

Mon, October 10 2022

Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions

DALLAS & EDMONTON, Alberta--(BUSINESS WIRE)-- Celanese Corporation (NYSE: CE), a global chemical and specialty materials company, today announced an investment in expanded capabilities to meet high global demand for pharmaceutical-grade polymers used in the development of implants and inserts for sustained-release drug delivery. The new 1,000-square-foot cleanroom facility, located in Edmonton, Alberta, will focus on cryogenic micronization of VitalDose® EVA material into a powder form that is ready to be blended with small molecules and biologics.

“Our VitalDose® technology is already used in sustained-release drug delivery applications for effective, patient-centric drug delivery for certain ophthalmic diseases, addictive disorders and contraception,” said Susan Rahe, senior director, Celanese pharmaceutical solutions. “Availability of pharmaceutical-grade polymers with broad molecule compatibility is vital to development of innovative drug delivery solutions that provide an improved patient experience. We see an opportunity to improve the future treatment of cancer, retinal disorders and certain disorders of the central nervous system, with the potential to meaningfully improve the lives of people around the world.”

Today’s news builds on the 2021 opening of the Celanese Pharmaceutical Development & Feasibility Lab. The micronizer and clean room facility are being prepared to supply VitalDose® EVA in powder form by early 2023.

“We understand that providing cryogenic grinding reduces complexity for our global customers, allowing them to focus on accelerating the time to market for their solutions,” added Dirk Hair, director, technical and quality assurance at the Celanese Edmonton facility. “Pharmaceutical companies will have the benefit of integrated material production and cryogrinding from our manufacturing facility with the same high-quality standards they’ve come to expect from Celanese.”

Celanese offers cutting-edge medical and pharmaceutical material solutions and expert development support to Pharmaceutical and Medical Device companies worldwide. With more than 40 years of experience supporting key applications and the demanding requirements of the medical market, Celanese is expanding design possibilities as its customers find new ways to deliver a sustained dose of medication over time. For more information on VitalDose technology, visit: www.vitaldose.com.

About Celanese

Celanese Corporation is a global chemical leader in the production of differentiated chemistry solutions and specialty materials used in most major industries and consumer applications. Our businesses use the full breadth of Celanese's global chemistry, technology and commercial expertise to create value for our customers, employees, shareholders and the corporation. As we partner with our customers to solve their most critical business needs, we strive to make a positive impact on our communities and the world through The Celanese Foundation. Based in Dallas, Celanese employs approximately 8,500 employees worldwide and had 2021 net sales of $8.5 billion. For more information about Celanese Corporation and its product offerings, visit www.celanese.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221010005191/en/

Investor Relations
Brandon Ayache
+1 972 443 8509
brandon.ayache@celanese.com

Media Relations – Global
Brian Bianco
+1 972 443 4400
media@celanese.com

Media Relations Europe (Germany)
Petra Czugler
+49 69 45009 1206
petra.czugler@celanese.com

Source: Celanese Corporation